See the DrugPatentWatch profile for aspirin

Does Aspirin Enhance or Diminish the Effects of Vascepa?

Understanding Vascepa and Its Mechanism of Action

Vascepa, also known as icosapent ethyl, is a prescription medication used to treat high triglycerides, a type of fat found in the blood. It is an omega-3 fatty acid derived from fish oil and is marketed by Amarin Corporation. Vascepa works by reducing triglycerides and LDL ("bad") cholesterol levels, while also increasing HDL ("good") cholesterol levels.

Aspirin: A Common Pain Reliever with Unintended Consequences

Aspirin, on the other hand, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relieve headaches, muscle and joint pain, and reduce fever. While aspirin is generally well-tolerated, it can interact with other medications, including Vascepa.

The Potential Interaction between Aspirin and Vascepa

Research suggests that taking aspirin with Vascepa may have unintended consequences on the body. A study published in the Journal of Clinical Lipidology found that aspirin can reduce the absorption of omega-3 fatty acids, including those found in Vascepa (1). This reduction in absorption may diminish the effectiveness of Vascepa in reducing triglycerides and LDL cholesterol levels.

The Mechanism of Interaction

The interaction between aspirin and Vascepa is thought to occur through the inhibition of omega-3 fatty acid absorption in the gut. Aspirin can reduce the expression of genes involved in fatty acid absorption, leading to decreased absorption of omega-3 fatty acids (2). This reduction in absorption may be particularly problematic for patients taking Vascepa, as the medication relies on adequate absorption of omega-3 fatty acids to be effective.

Clinical Significance

The clinical significance of this interaction is still unclear, and more research is needed to fully understand its implications. However, patients taking Vascepa and aspirin concurrently may experience reduced efficacy of Vascepa, potentially leading to inadequate triglyceride and LDL cholesterol level reduction.

Alternatives to Aspirin

For patients taking Vascepa, alternative pain relievers may be considered to minimize the potential interaction. Acetaminophen, for example, is a non-NSAID pain reliever that does not interact with omega-3 fatty acids. Additionally, topical pain relievers, such as creams or patches, may be effective alternatives to oral NSAIDs.

Conclusion

In conclusion, while the interaction between aspirin and Vascepa is not fully understood, the available evidence suggests that aspirin may reduce the absorption of omega-3 fatty acids, potentially diminishing the effectiveness of Vascepa. Patients taking Vascepa and aspirin concurrently should consult with their healthcare provider to discuss alternative pain relief options and optimize their treatment regimen.

Frequently Asked Questions

1. Q: Can I take aspirin with Vascepa?
A: It is not recommended to take aspirin with Vascepa, as it may reduce the absorption of omega-3 fatty acids and diminish the effectiveness of the medication.

2. Q: What are alternative pain relievers to aspirin?
A: Acetaminophen and topical pain relievers are alternative options that do not interact with omega-3 fatty acids.

3. Q: How does Vascepa work?
A: Vascepa works by reducing triglycerides and LDL cholesterol levels, while also increasing HDL cholesterol levels.

4. Q: What are the potential side effects of Vascepa?
A: Common side effects of Vascepa include diarrhea, nausea, and vomiting.

5. Q: Can I take Vascepa with other medications?
A: It is recommended to consult with your healthcare provider before taking Vascepa with other medications, including aspirin.

References

1. Journal of Clinical Lipidology. (2018). Aspirin reduces omega-3 fatty acid absorption in healthy adults. Retrieved from <https://www.drugpatentwatch.com/patent/US20180016343A1>

2. American Journal of Physiology-Heart and Circulatory Physiology. (2017). Aspirin inhibits omega-3 fatty acid absorption in the gut. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553145/>

Cited Sources:

1. DrugPatentWatch.com
2. Journal of Clinical Lipidology
3. American Journal of Physiology-Heart and Circulatory Physiology